Related references
Note: Only part of the references are listed.ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation
Nauras Shuker et al.
CLINICA CHIMICA ACTA (2012)
Population Pharmacokinetics and Pharmacogenetics of Everolimus in Renal Transplant Patients
Dirk Jan A.R. Moes et al.
CLINICAL PHARMACOKINETICS (2012)
PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo
Kathrin Klein et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Human Pregnane X Receptor Genotype of the Donor but Not of the Recipient Is a Risk Factor for Delayed Graft Function After Renal Transplantation
I. A. Hauser et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Donor age and ABCB1 1199G>A genetic polymorphism are independent factors affecting long-term renal function after kidney transplantation
Martine De Meyer et al.
JOURNAL OF SURGICAL RESEARCH (2012)
The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients
Kelly A. Birdwell et al.
PHARMACOGENETICS AND GENOMICS (2012)
Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients
Yi Li et al.
TRANSPLANT IMMUNOLOGY (2012)
Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation
Guillermo Gervasini et al.
TRANSPLANT INTERNATIONAL (2012)
Mycophenolic Acid-Related Anemia and Leucopenia in Renal Transplant Recipients Are Related to Genetic Polymorphisms in CYP2C8
Rachida Bouamar et al.
TRANSPLANTATION (2012)
A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients
Laure Elens et al.
CLINICAL CHEMISTRY (2011)
Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes
Beatriz Tavira et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2011)
Influence of Cytochrome P450 3A5 (CYP3A5) Genetic Polymorphism on the Pharmacokinetics of the Prolonged-Release, Once-Daily Formulation of Tacrolimus in Stable Renal Transplant Recipients
Francois Glowacki et al.
CLINICAL PHARMACOKINETICS (2011)
Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers
Hui-Lin Tang et al.
PHARMACOGENETICS AND GENOMICS (2011)
Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients
Laure Elens et al.
PHARMACOGENOMICS (2011)
The P450 oxidoreductase*28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients
Hylke de Jonge et al.
PHARMACOGENOMICS (2011)
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
D. Wang et al.
PHARMACOGENOMICS JOURNAL (2011)
Genetic Determinants of Mycophenolate-Related Anemia and Leukopenia After Transplantation
Pamala A. Jacobson et al.
TRANSPLANTATION (2011)
CYP3A5 Genotype Does Not Influence Everolimus In Vitro Metabolism and Clinical Pharmacokinetics in Renal Transplant Recipients
Nicolas Picard et al.
TRANSPLANTATION (2011)
Expression of CYP3A5 and P-glycoprotein in Renal Allografts With Histological Signs of Calcineurin Inhibitor Nephrotoxicity
Christoph Metalidis et al.
TRANSPLANTATION (2011)
Associations of ABCB1 3435C>T and IL-10-1082G>A Polymorphisms With Long-Term Sirolimus Dose Requirements in Renal Transplant Patients
Wai-Johnn Sam et al.
TRANSPLANTATION (2011)
Correlation of IMPDH1 Gene Polymorphisms with Subclinical Acute Rejection and Mycophenolic Acid Exposure Parameters on Day 28 after Renal Transplantation
Hideaki Kagaya et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2010)
Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8*2 variant allele
Jean-Baptiste Woillard et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II
Christine E. Staatz et al.
CLINICAL PHARMACOKINETICS (2010)
Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I
Christine E. Staatz et al.
CLINICAL PHARMACOKINETICS (2010)
The Role of Organic Anion-Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid Pharmacokinetics
N. Picard et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Donor P-gp Polymorphisms Strongly Influence Renal Function and Graft Loss in a Cohort of Renal Transplant Recipients on Cyclosporine Therapy in a Long-Term Follow-Up
J-B Woillard et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Dosing Tacrolimus Based on CYP3A5 Genotype: Will It Improve Clinical Outcome?
T. van Gelder et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Explaining variability in ciclosporin exposure in adult kidney transplant recipients
Rogier R. Press et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Long-Term Changes in Cyclosporine Pharmacokinetics After Renal Transplantation in Children: Evidence for Saturable Presystemic Metabolism and Effect of NR1I2 Polymorphism
Samuel Fanta et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis
Hui-Lin Tang et al.
PHARMACOGENETICS AND GENOMICS (2010)
Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil
Olivier Gensburger et al.
PHARMACOGENETICS AND GENOMICS (2010)
Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase
Vishal Agrawal et al.
PHARMACOGENETICS AND GENOMICS (2010)
CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation
Arnaud Capron et al.
PHARMACOGENOMICS (2010)
The Pharmacogenetics of Calcineurin Inhibitor-Related Nephrotoxicity
Dennis A. Hesselink et al.
THERAPEUTIC DRUG MONITORING (2010)
Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects
Yong Zeng et al.
ACTA PHARMACOLOGICA SINICA (2009)
Effect of Mycophenolate Acyl-Glucuronide on Human Recombinant Type 2 Inosine Monophosphate Dehydrogenase
Olivier Gensburger et al.
CLINICAL CHEMISTRY (2009)
Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients
Khaled Benkali et al.
CLINICAL PHARMACOKINETICS (2009)
UGT1A9-275T > A/-2152C > T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus-Treated Kidney Transplant Patients
R. H. N. van Schaik et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients
W. Zhao et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
ABCB1 Genotypes Predict Cyclosporine-Related Adverse Events and Kidney Allograft Outcome
Dario Cattaneo et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Donor Age and Renal P-Glycoprotein Expression Associate with Chronic Histological Damage in Renal Allografts
Maarten Naesens et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India
Ranjana Singh et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2009)
Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism
Ferdi Sombogaard et al.
PHARMACOGENETICS AND GENOMICS (2009)
Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease
Michael Rudnicki et al.
PHARMACOGENOMICS (2009)
Genetic Polymorphisms of MRP2 and UGT2B7 and Gastrointestinal Symptoms in Renal Transplant Recipients Taking Mycophenolic Acid
Jae Wook Yang et al.
THERAPEUTIC DRUG MONITORING (2009)
The Prevalence of Uridine Diphosphate-Glucuronosyltransferase 1A9 (UGT1A9) Gene Promoter Region Single-Nucleotide Polymorphisms T-275A and C-2152T and Its Influence on Mycophenolic Acid Pharmacokinetics in Stable Renal Transplant Patients
A. I. Sanchez-Fructuoso et al.
TRANSPLANTATION PROCEEDINGS (2009)
Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9
Zheng Jiao et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in Caucasian patients with androgen-independent prostatic cancer
Akinobu Hamada et al.
CLINICAL CANCER RESEARCH (2008)
Current target ranges of mycophenolic acid exposure and drug-related adverse events: A 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients
Dirk R. J. Kuypers et al.
CLINICAL THERAPEUTICS (2008)
Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors
L'Aurelle A. Johnson et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients
Dennis A. Hesselink et al.
PHARMACOGENETICS AND GENOMICS (2008)
Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms
Samuel Fanta et al.
PHARMACOGENETICS AND GENOMICS (2008)
Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients
Severine Crettol et al.
PHARMACOGENETICS AND GENOMICS (2008)
CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine
R. Kreutz et al.
PHARMACOGENOMICS JOURNAL (2008)
Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations
Ningwu Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Association of four DNA polymorphisms with acute rejection after kidney transplantation
Josep Grinyo et al.
TRANSPLANT INTERNATIONAL (2008)
Haplotypic Structure of ABCB1/MDR1 Gene Modifies the Risk of the Acute Allograft Rejection in Renal Transplant Recipients
Stepan Bandur et al.
TRANSPLANTATION (2008)
Association of C-509T and T869C polymorphisms of transforming growth factor-β1 gene with chronic allograft nephropathy and graft survival in Korean renal transplant recipients
J. -H. Cho et al.
TRANSPLANTATION PROCEEDINGS (2008)
Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients
W. -X. Zhang et al.
XENOBIOTICA (2008)
IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients
J. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients
Li-Yan Miao et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2008)
Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients
Masatomo Miura et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
CYP3A5 and CYP3A4 but not MDR1 single-nucleotide Polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients
D. R. J. Kuypers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation
Laure Elens et al.
PHARMACOGENETICS AND GENOMICS (2007)
C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation
Sara Baldelli et al.
PHARMACOGENOMICS (2007)
Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity
Melanie S. Joy et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on acyl-MPAG production in vitro and in adult renal transplant patients
Nassim Djebli et al.
PHARMACOGENETICS AND GENOMICS (2007)
A novel variant L263F in human inosine 5′-monophosphate dehydrogenase 2 is associated with diminished enzyme activity
Jian Wang et al.
PHARMACOGENETICS AND GENOMICS (2007)
Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5
Nicolas Picard et al.
DRUG METABOLISM AND DISPOSITION (2007)
Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects
Y.-F. Hu et al.
XENOBIOTICA (2007)
Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients
Hideaki Kagaya et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers
E. Levesque et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients
L. Renders et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
A silent polymorphism in the MDR1 gene changes substrate specificity
Chava Kimchi-Sarfaty et al.
SCIENCE (2007)
Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients
Christine E. Staatz et al.
CLINICAL PHARMACOKINETICS (2007)
Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation
Yong-Fang Hu et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2006)
CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates:: Guidelines from an experimental study
V. Haufroid et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients
Maarten Naesens et al.
TRANSPLANTATION (2006)
MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells
Noha N. Salama et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid
Olivier Bernard et al.
DRUG METABOLISM AND DISPOSITION (2006)
CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients
Yannick Le Meur et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Role of MRP2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: Effect of cyclosporine
IS Westley et al.
DRUG METABOLISM AND DISPOSITION (2006)
Sirolimus population pharmacokinetic/pharmacogenetic analysis and Bayesian modelling in kidney transplant recipients
Nassim Djebli et al.
CLINICAL PHARMACOKINETICS (2006)
Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids
M Mourad et al.
TRANSPLANTATION (2005)
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability
DX Wang et al.
PHARMACOGENETICS AND GENOMICS (2005)
The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGTIA9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients
DRJ Kuypers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus
LK Kamdem et al.
CLINICAL CHEMISTRY (2005)
ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation
IA Hauser et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy
D Anglicheau et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Tacrolimus pharmacogenetics: The CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and south Asians
IAM MacPhee et al.
TRANSPLANTATION (2005)
Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism
N Picard et al.
DRUG METABOLISM AND DISPOSITION (2005)
Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus
Y Zhao et al.
TRANSPLANTATION PROCEEDINGS (2005)
CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation
D Anglicheau et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients
V Haufroid et al.
PHARMACOGENETICS (2004)
A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity
Y Duguay et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism
HX Zheng et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein
EL Woodahl et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants
O Bernard et al.
DRUG METABOLISM AND DISPOSITION (2004)
Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver
H Girard et al.
PHARMACOGENETICS (2004)
Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic-polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes
DA Hesselink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation
M Goto et al.
PHARMACOGENETICS (2004)
The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation
IAM MacPhee et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients
N Tsuchiya et al.
TRANSPLANTATION (2004)
The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients
R Kreutz et al.
PHARMACOGENETICS (2004)
Transforming growth factor beta and progression of renal disease
P August et al.
KIDNEY INTERNATIONAL (2003)
Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients
E Thervet et al.
TRANSPLANTATION (2003)
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
DA Hesselink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms
HX Zheng et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2003)
Increased transcriptional activity of the CYP3A4* 1B promoter variant
B Amirimani et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2003)
Association of the P-glycoprotein transporter MDR1C3435T polymorphism with the susceptibility to renal epithelial tumors
M Siegsmund et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2002)
Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients
M Shipkova et al.
THERAPEUTIC DRUG MONITORING (2002)
Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3
YH Huang et al.
PHARMACOGENETICS (2002)
NADPH-cytochrome P450 oxidoreductase - Structural basis for hydride and electron transfer
PA Hubbard et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells
M Hitzl et al.
PHARMACOGENETICS (2001)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl et al.
NATURE GENETICS (2001)
The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes
M Shipkova et al.
TRANSPLANTATION PROCEEDINGS (2001)
Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance
LP Rivory et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Share Paper
